Portage Biotech (NASDAQ:PRTG – Get Rating) and Lekoil (OTCMKTS:LEKOF – Get Rating) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, profitability and earnings.
Insider and Institutional Ownership
1.0% of Portage Biotech shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a summary of recent recommendations and price targets for Portage Biotech and Lekoil, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valuation and Earnings
This table compares Portage Biotech and Lekoil’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Portage Biotech||N/A||N/A||-$16.87 million||($1.16)||-8.02|
|Lekoil||$32.92 million||N/A||-$108.05 million||N/A||N/A|
Portage Biotech has higher earnings, but lower revenue than Lekoil.
Risk & Volatility
Portage Biotech has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Comparatively, Lekoil has a beta of -1.19, suggesting that its share price is 219% less volatile than the S&P 500.
This table compares Portage Biotech and Lekoil’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Portage Biotech beats Lekoil on 5 of the 8 factors compared between the two stocks.
About Portage Biotech
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Lekoil Limited explores for, develops, and produces crude oil and natural gas primarily in Nigeria. The company owns 40% interest in the Otakikpo marginal field located in the south-eastern part of the Niger Delta; 45% participating interest in the OPL 276 located in the eastern Niger Delta basin; 62% participating interest in the OPL 325; and 17.14% participating interest in the OPL 310 block situated in the Upper Cretaceous fairway that runs along the West African Transform Margin. The company has a strategic alliance agreement with NAMCOR Exploration and Production (PTY) Limited. Lekoil Limited was founded in 2010 and is headquartered in Lagos, Nigeria.
Receive News & Ratings for Portage Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portage Biotech and related companies with MarketBeat.com's FREE daily email newsletter.